Charles Padala | IR |
Dror Bashan | President and CEO |
Eyal Rubin | SVP and CFO |
Boobalan Pachaiyappan | H.C. Wainwright |
John Vandermosten | Zacks |
Unidentified Analyst | Private Investor |
Good morning, ladies and gentlemen and welcome to the Protalix BioTherapeutics Conference for Second Quarter 2023 Financial Business Results.
As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mr. Chuck Padala with LifeSci Advisors, Investor Relations for Protalix. Thank you, you may begin the conference.